EMA Recommends Orphan Drug Status for Psoriasis Treatment

The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion for orphan drug designation for imsidolimab. This investigational treatment targets generalized pustular psoriasis (GPP), a severe and chronic inflammatory skin condition. This recommendation highlights the significant unmet medical need for GPP patients in the European Union.